A phase I trial of first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers.
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Claudin 18.2 CAR T cell therapy (Primary)
- Indications Gastric cancer; Pancreatic cancer
- Focus Adverse reactions
- 07 Sep 2018 Results published in the CARsgen Media Release
- 07 Sep 2018 According to a CARsgen media release, data from this trial were presented at 2018 CAR-TCR Summit.
- 12 Aug 2017 New trial record